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Cancer is considered the second leading cause of death after heart attack. Different treatments
have been applied to kill cancer cells such as chemotherapy, which is the use of chemicals or
drugs in order to treat cancer cells. Platinum-based anti cancer drugs are the backbone of
chemotherapy, they play a crucial role in treating various malignant tumor. However, the
disadvantages of these drugs are very painful on patients, such as nephrotoxicity and ototoxicity.
In the last four decades, thousands of platinum-based anticancer drugs have been synthesized for
hope in find a new drug with higher efficacy and less side effects.In this study, three different
types of platinum-based anticancer drugs are considered. The first type, chelate agents, which
provides stability and force the drug to form with cis configuration. Five out of six of the
approved platinum-based anticancer drugs have bidentate ligands, which proves the advantages
for synthesis of new drugs with bidentate amine ligands. The second type, Pt(IV)-based
complexes, which is an active field due to the benefits that octahedral complexes provide. None
of Pt(IV) drug has been approved, however; three drugs are undergoing clinical trail. This field is
quite interesting for further investigations. The third type, π-bond binding, whihc is a new study
of organic couplings that can bind to metal center by the pi bond instead of the nitrogen, this new
feature can lead to a new field where it can be used for anticancer drug, or by inhibiting COX
enzyme, the enzyme that causes pain. Fiver differentt drugs have been synthesized, and they are
DPAPlatin, PhenPlatin, TriPicolyAminePlatin, DiPhenPlatin, and DCCplatin.
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CHAPTER 1
INTRODUCTION
1.1.Cancer
A universal health concern, that is the main reason of approximately 13% of all types of human deaths around the world, is cancer. Even though noteworthy processes have been studied,
including chemotherapy, there is a significant increase in cancer diagnosis; around 25 million of
the world population are suffering from this devastating disease [1]. The antitumor drug, cisplatin, figure 1, discovered in the 1960s, has become one of the most useful agents to treat different types of cancer [2]. Nowadays, it has been used in over 50% of cancer treatments [3]. Over
100 drugs have been studied, tested and used to date in chemotherapy. Drugs are used based on
specific kinds of cancer. By reason of their cytotoxic activity, platinum and its derivatives play
an important role in anti-tumor drugs, and cisplatin can be a very useful prototype [4]. However,
cisplatin has major side effects which have reduced the efficacy of using it. These include
nephrotoxicity, myelotoxicity, neurotoxicity, nausea, and vomiting, as well as harming healthy
cells due to insufficient specificity in targeting of tumor cells [5]. All those drawbacks have been
an incentive to scientists to overcome them with better solutions which would not affect healthy
cells.

Figure 1. Cancer statistics in the U.S. in 2015.
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1.1.1. Cancer treatment
There are many factors to determine cancer treatment including the stage of the cancer, the
size of the tumor and finally whether it is just a tumor or metastatic cancer. Depending on all the
previous concepts, cancer treatment would be one or more the following: surgery, hormonal therapy, immunotherapy, radiation treatment, and chemotherapy [6,7].

1.1.1.1 Surgery
Surgery is one of the cancer treatments which relies on removal of the cancerous cells and tissues. Surgery might require other treatment such as chemotherapy or radiation treatment in order
to eliminate residual cancer cells, decrease the scale of the tumor or to prevent the cancer from
growing, spreading or re-occurring [8].

1.1.1.2 Hormone therapy
Blocking estrogen from the estrogen receptor, ER, is how hormone therapy functions, or even
by preventing estrogen from bio-synthesizing itself. It is recommended for ER+ breast cancer
cases [9,10].

1.1.1.3 Immunotherapy
Various studies have hinted at the capability of the immune system to attack the protein that
supports the growth of cancer cells [11].

1.1.1.4 Radiation therapy
Due to its high energy, radiation treatment can kill cells by damaging their DNA. It has been
used for more than 20 years and its function is to kill cancer cell by targeting them with the radiation beam. However, the difficulties of targeting just the tumor cells without damaging some
healthy cells are limitations to its use [12].

1.1.1.5 Targeted therapy
As previously mentioned, poor selectivity and specificity are drawbacks in chemotherapy;
studies have been carried out in order to make improvements, and that has led to drug targeting
delivery, DTD. Due to its avoidance of damaging normal cells and the restraint drug resistance,
DTD represents a very promising step which has been called ‘magic bullet’. The main reason of
!2

these endeavors is to develop platinum drugs that are significantly selective for tumor cells and
can be administered at lower doses with fewer side effects and an improved therapeutic index
[13].

1.1.1.6 Chemotherapy

Chemotherapy means using chemicals or drugs to treat a disease. In the case of cancer, it
means to use drugs in order to kill the cancer cells, and when possible to kill them selectively
[14].

1.1.2 Approved platinum-based drugs

According to US the Food and Drug Administration, FDA, several cancer drugs have been approved in 2014. Listed below are the names of the approved cancer drugs in 2014, and a there
are a lot more from previous years. The approved cancer drugs are Pembrolizumab, bevacizumab, idelalisib, belinostat, ceritinib, mercaptopurine, siltuximab, ramucirumab, ofatumumab, ibrutinib, and trametinib [15].

1.1.3 Side effect of platinum-based drugs
Unfortunately, cancer drugs are generally not selective, which means they attack healthy cells
as well as cancer and tumor cells. The pain that they leave, as well as the long period of time of
treatment, which can take up to five years, actually cause some people to give up on the treatment. Various side effects might occur such as nephrotoxicity, myelotoxicity, neurotoxicity, nausea, and vomiting. The current studies are made in order to obtain a safer drug delivery with lower toxicity and higher selectivity [16].

1.1.4 Platinum-based complexes
Platinum-based anticancer drugs occupy a crucial role in the treatment of various malignant
tumors. However, the efficacy and applicability of platinum drugs are heavily restricted by severe systemic toxicities and drug resistance. Different drug targeting and delivery (DTD) strategies have been developed to prevent the shortcomings of platinum-based chemotherapy [13].
Platinum (II) complexes are commonly used in cancer chemotherapy [17]. “Classical” Pt(II)drug complexes[18,19] are cisplatin (trade names Platinol and Platinol-AQ), carboplatin, oxali!3

platin, nedaplatin, lobaplatin, and heptaplatin. Cisplatin is one of the most potent antitumor drugs
against solid tumors, such as ovarian, testicular, lung, head, neck, and bladder cancers [20]. Its
anticancer activity results from the formation of stable DNA-Pt complexes through intra-strand
cross-links, resulting in alteration of the DNA structure, which prevents replication and favors
initiation of apoptosis. Cisplatin is unstable in water with a first hydrolysis half time t1/2 ~2h at
37°C. Consequently, cisplatin must be administered in a saline solution maintaining the chemical
neutrality essential for a rapid penetration of cisplatin into the cells through passive diffusion
process. The Pt-Cl bond is stable only when the chloride concentration is high (>100 mM) as in
the blood. However, different research works have been carried out with different results [21].
Due to its side effects, however, cisplatin and its derivatives have drawbacks, which have led scientists to attempt different methods and ingredients in order to obtain better specificity to target
the tumor cells and not spread to other healthy cells. Recently, a new discovery has been published, by engaging nanomedicine, which has become a very useful method in these years. Gold
nanoparticles, for instance, were tried in order to enhance cytotoxic activity in bile acid cisplatin
derivatives [22]. Cisplatin units have also been attached to bile acids in oder to make them more
biocompatible and target them better to colorectal cancers [23,24].

1.2 Platinum-based anticancer drugs
Platinum-based anticancer drugs play an important role in treating various malignant tumors.
They are the backbone of drugs that are clinically used for the treatment of different solid tumors: for instance, genitourinary, colorectal, and non-small cell lung cancers. Cisplatin, the primary anticancer drug, has been widely used for more than thirty years in standard chemotherapy
procedures, either as a single therapeutic technique or in combination with other cytotoxic agents
or radiotherapy [25]. It has shown some spectacular successes. Nonetheless, platinum-based anticancer chemotherapy is associated with serious side effects because of poor specificity [26].
Especially for cisplatin, systemic toxicities like nephrotoxicity, neurotoxicity, ototoxicity, and
emetogenesis impose severe disorders or injuries on patients while the treatment is taking place,
which restrict its efficacy greatly [27]. Additionally, the efficacy of cisplatin is often limited by
the intrinsic and acquired resistance possessed by various cancers [28]. Various mechanisms have
been proposed in order to elucidate and explain the reason behind cellular resistance to cisplatin
and its analogues in preclinical models [29].
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Four representatives have been introduced, and they are:
Decreased drug accumulation or increased drug efflux.
Increased detoxification of the drug by sulfur-containing molecules within the cells.
Enhanced repair and increased tolerance to DNA damage.
Changes in molecular pathways involved in the regulation of cell survival or cell death.
The disadvantages of cisplatin have given momentum for the improvement of platinum-based
anticancer drugs. For the last four decades, thousands of platinum complexes have been prepared, designed and developed in the hope of finding new drugs with a more tolerable toxicological profile and higher efficacy. These efforts have brought five different drugs into clinical use,
and they are carboplatin, oxaliplatin, nedaplatin, lobaplatin, and heptaplatin. Each of these newly
designed drugs show some advantages over cisplatin. For example, nedaplatin shows less
nephrotoxicity and neurotoxicity than cisplatin and carboplatin. Oxaliplatin, on the other hand,
reveals less toxicity and little, or no cross resistance, to cisplatin or carboplatin[30].
In order to explain the idea of how to further advance the field, the primary concern in the development of platinum anticancer agents is the drug resistance as well as systemic toxicity. This
main goal is to prepare and develop anticancer drugs that can go directly to a cancerous cell and
destroy it without harming normal cells. However, this goal is basically elusive for such a complicated disease as cancer. Nonetheless, it is possible to contemplate the ideal scenario by developing platinum-based prodrugs that can be protected and safe in the administered form but are
cytotoxic to cancer cells after being activated under certain conditions.
Obviously, the understanding of this ideal is driven by the tumor selectivity of platinum complexes. Generally, there are at least three advantages platinum complexes should have in the design of new anticancer drugs [31]:
Constructing complexes that display different DNA-binding modes;
Exploiting prodrugs that can be activated only in the tumor tissues;
Improving drug accumulation at the tumor site by means of an accurate targeting and delivery
strategy.

The first advantage incorporates polynuclear platinum complexes, trans-platinum complexes,
and monofunctional platinum complexes [32]. The second one includes complexes that employ
the unique characters of solid tumors, such as acidic pH, and hypoxic or reducing conditions. For
instance, inert platinum(IV) complexes can be reduced to cytotoxic platinum(II) complexes after
being administered with the loss of the two axial ligands under hypoxic conditions in the tumor
tissue, and thus, act as prodrugs [33]. This third category is ameliorating the selective accumulation of platinum drugs in healthy tissues through targeting and delivery techniques [13].
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Figure 2. Approved platinum-based anticancer drugs.

1.2.1. Platinum complexes and nitrogen-donor ligands
The functionality of platinum-based anticancer drugs is quite similar to alkylating agents as
they both go directly to and damage DNA in order to prevent cancer cell from growing and reproducing. However, these agents work in all phases of the cycle, which means that they are not
phase-specific. Yet, platinum-based anticancer drugs are less likely than the alkylating agents to
cause leukemia later on [34]. Plainly, all of the clinically established platinum-based anticancer
drugs are endowed with nitrogen-donor ligands that are strongly bound to the metal center. Generally, these ligands are not substituted (released) as the platinum compound exerts its anticancer
effect. Nevertheless, the nature of the N-donor ligands dramatically influences the anticancer
properties of platinum complexes and leads to activity against different types of cancers [35].
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1.2.2. History of platinum-based drugs
Platinum had been thought to have no biological activity until Barnett Rosenberg and colleagues, in Michigan, applied electric current E. Coli using platinum electrodes. The bacterial
cells stopped dividing, although they kept growing to up to 300 times their normal length (“filamentation”). Surprisingly, the researchers discovered that the electric current or voltage was not
responsible for the bacterial growth. Instead, the electric current had led to the formation of a
new chemical species, and the main new compound so produced caused the filamentation. The
compound was determined to be cis-(NH3)2 PtCl2, which turns out to be Peyrone’s salt, discovered in 1845 by Michele Peyrone [36] , and this, not the electrical field was controlling cell division. This experiment was called “accidental discovery that led eventually to cisplatin” by Dr.
Barnett Rosenberg in Michigan.
For a long time, Dr. Rosenberg and his colleagues did not know what they had discovered. It
was thought that they might have found a way to control cell growth with electrical currents.
Two years were spent in order to discover the reason why the electrical field appeared to have
such a profound effect. Finally, it was realized that the cell division was being blocked not by the
electric field, but by a platinum compound released from the electrodes. Once they recognized
the compound that controlled cell division so dramatically it was renamed cisplatin [37].

1.2.3. Mechanism of action
Cisplatin is believed to apply its anticancer features by crosslinking and intercalating with
DNA, causing cell death “apoptosis” [38]. After introduction into the bloodstream of a patient,
cisplatin faces a high concentration of chloride in the blood plasma, which is around 100 mM,
and the high concentration does not allow the replacement of its chloride ligands by water molecules, i.e. the process of aquation is prevented. Nonetheless, cisplatin is vulnerable to attack by
proteins found in blood plasma, in particular those that have thiol groups, such as human serum
(albumin) and the amino acid (cysteine). As a matter of fact, studies have shown that one day
after cisplatin administration, more than 50% of the platinum in blood plasma is protein bound
[39]. This protein is able to deactivate the drug [40] and some of the severe side effects of cisplatin treatment [39]. However, this drug is formed together with the trans formation which is not
very cytotoxic, but is toxic and should be removed before treatment. The concentration of the
chloride decreases inside cells, which is between 2 to 30 mM and there replacement can take a
place [41].
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Figure 3. Mechanism of action of cisplatin “The Discovery and Development of Cisplatin” (R.
A. Alderden, M. D. Hall, and T. W. Hambley. J. Chem. Ed. 2006 83(5), 728-734) [42].
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1.3. Pt(IV)-based complexes
Nowadays, the Pt(IV) compounds have been investigated for possible anti-tumor activity in
order to obtain better understanding of whether these platinum(IV)-based complexes can be
drugs or just act as prodrugs. If the latter, it would mean that they are reduced to Pt(II) before
reaching their DNA target, which is the common belief [43]. A prodrug is defined as a compound
that gets converted within the body to the active form. It is usually used when the normal active
drug is either too toxic when directly administrated, or is difficult to absorb, or has the possibility
of breaking down before it reaches the target. Pt(IV) is kinetically more inert than Pt(II), which
means Pt(IV) drugs are more stable to acidic media, so that they may better survive the conditions present in the stomach, and thus can be administered orally [44]. Pt(IV) drugs are of particular interest since they may be toxic to tumors which are normally resistant to cisplatin.
Different platinum(IV) complexes have been under clinical trials, but none has been approved
by FDA for clinical use in the United States. These drugs are iproplatin, tetraplatin, and
satraplatin.

Iproplatin

Satraplatin

Tetraplatin

Figure 4. Pt(IV)-based complexes that are going under clinical trail.
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1.3.1 Structure activity

One of the additional feature of platinum(IV) complexes is the six-coordinate octahedral coordination geometry. Having two additional ligands allows for further tuning of the properties.
6

Additionally, these complexes are basically more inert due to being d octahedral metal ions.
Therefore, the deactivation of the drugs that can occur when they interact with thiol is prevented
by using platinum(IV)-based anticancer drugs [45]. As platinum(IV)-based complexes are inert,
the reduction to Pt(II) usually occurs before binding to the target, DNA [46]. Reduction of Pt(IV)
happens with loss of two ligand, leading to the square planar geometry characteristic of Pt(II)
complexes. It is believed that the (monodentate) ligands that are located trans to each other will
be lost in the reduction step. Once the loss of two ligands occurs, the mechanism of action of
Pt(IV) prodrug will be fairly similar to cisplatin, where it binds to the plasma protein and then
the loss of chloride will occur after substituting it with water molecule, which is highly reactive
towards nucleus, then the formation of Pt-DNA will take a place in order to prevent the cell from
dividing and growing [47].

1.3.2 Proposed mechanism of action
After detecting Pt-DNA adducts of platinum(IV)-based anticancer drugs, they were found to
have identical bonding linkages to those of Pt(II) complexes, and that led to a belief that a similar mechanism of action could apply to unreduced platinum(IV) complexes [48].
1.4. Attaching metal center to π-bond of organic compound
The Dewar–Chatt–Duncanson model is a type of organometallic chemistry, which describes
the category of chemical attachment between an alkene and a metal, π complex, in some
organometallic complexes. This feature has been named after Michael J. S. Dewar, Joseph Chatt
and L. A. Duncanson [49].
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The action takes a place when pi-acid alkene donates electron density to the platinum d-orbital
from a π symmetry bonding orbital between the carbon atoms. Then, platinum donates electrons
back from another filled d-orbital into the vacant π antibonding orbital. These two effects contribute to decrease the carbon-carbon bond order, resulting in an elongated C-C distance and a
reduction of the vibrational frequency.
One of the well-known examples is Zeise's salt K[PtCl3(C2H4)].H2O, which is believed to be
the first organometallic [50], the C-C bond length has increased to 1375 picometers from 1337
pm for ethylene [51]. This cooperation motivates the carbon atoms to rehybridize from sp2 to sp3,
which is determined by the bending of the hydrogen atoms on the ethylene back away from the
metal [52].

The application of a cytotoxic COX inhibitor opens a new option for the therapy of tumors for
which it is known that an overexpression of COX results in pathological variations. During the
last years it was demonstrated that various mammary carcinoma show increased expression of
COX-2 and that inhibitors of this enzyme can reduce tumor growth and tumor progression. An
increased COX-2 expression in gynecologic tumors is further accompanied by a bad prognosis
for patients with mammary carcinoma as well as prostate carcinoma [53].
1.5. Objectives of the study
Due to the severe systemic toxicity and side effects, alternative platinum-based anticancer
drugs are needed in order to obtain a drug that has lower or no side effects. For the last four
decades, thousands of platinum-based anticancer drugs have been synthesized for hope in finding
a new drug that can be administrated with lower dose and higher efficacy. Five new platinumbased anticancer drugs have been synthesized and categorized under three different types, and
they are:
Chelate agents or denticity. It provides the ability to have cis-configuration complexes which is
the desired configuration for platinum-based anticancer drugs.
Pt(IV)-based complexes. A highly active field with motivating results such as inertness before
reaching to target cells.
Platinum-π backbonding complexes. A new field with a unique property where platinum metal is
attached to the π bond of organic compounds.
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CHAPTER 2
CHARACTERIZATION OF NEW PT-BASED ANTI-CANCER DRUGS

2.1. Introduction
One of the objectives is to synthesize platinum-based anticancer drugs with fewer reaction
steps and higher yield. As this study has three different categories, it was necessary to have various procedures to follow. The synthesis of the first category, chelate agents, is done by having
starting materials together in water. The platinum center will react with the organic compound,
and the solvent to work as leaving group. Bidentate ligands have two donor atoms, and that allows them to bind to a central metal atom. Common examples of bidentate ligands are ethylenediamine, which can be used as a non-leaving group, and the oxalate ion, which can be used as
anionic leaving ligands. It bonds as nitrogen or oxygen atoms on the adjacent edges of a planar
Pt(II), each donor have two free electrons that can be used to bond to a central metal atom or ion.
However, none of the approved drugs has organic bidentate ligands and mono dentate anionic
ligand, which is worth trying, as it can have similar mechanism of action to the one of cisplatin.
If the leaving group is chloride such as DPAPlatin, its loss is important before binding to target
DNA. Another option to consider is having water molecule as leaving group instead of chloride,
such as the leaving group of PhenPlatin. In this case, it is believed that the complex is very reactive and can interact with target DNA without any additional step. A second possibility can be
applied to PhenPlatin, which is the loss of the second platinum, and that will lead to different
drugs which can be a benefit as two different drugs can be administrated at the same time.
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The second category “Pt(IV)-based complexes” differs from normal platinum-based anticancer drugs as it has two additional ligands that essentially keep the drugs inactive until they
reach target DNA. One of the additional feature of platinum(IV) complexes is the six-coordinate
octahedral coordination geometry. They have two additional ligands which allows for further
6
tuning of the properties. Additionally, these complexes are basically more inert due to being d
octahedral metal ions. Therefore, the deactivation of the original platinum(II) drugs that can occur when they interact with thiol is prevented by using platinum(IV)-based anticancer drugs [1].
As platinum(IV)-based complexes are inert, the reduction to Pt(II) usually occurs before binding
to the target, DNA [2]. Reduction of Pt(IV) happens with loss of two ligand, leading to the
square planar geometry characteristic of Pt(II) complexes. It is believed that the (monodentate)
ligands that are located trans to each other will be lost in the reduction step. Once the loss of two
ligands occurs, the mechanism of action of Pt(IV) prodrug will be fairly similar to cisplatin,
where it binds to the plasma protein and then the loss of chloride will occur after substituting it
with water molecule, which is highly reactive towards nucleus, then the formation of Pt-DNA
will take a place in order to prevent the cell from dividing and growing [3].
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Figure 7. The octahedral geometry of Pt(IV)-based complexes.
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The third category “ π-bond binding” can be a new and interesting field. The Dewar–Chatt–
Duncanson model is a type of organometallic chemistry, which describes the category of chemical attachment between an alkene and a metal, π complex, in some organometallic complexes.
This feature has been named after Michael J. S. Dewar, Joseph Chatt and L. A. Duncanson [4].
The action takes a place when pi-acid alkene donates electron density to the platinum d-orbital
from a π symmetry bonding orbital between the carbon atoms. Then, platinum donates electrons
back from another filled d-orbital into the vacant π antibonding orbital. These two effects contribute to decrease the carbon-carbon bond order, resulting in an elongated C-C distance and a
reduction of the vibrational frequency.
One of the well-known examples is Zeise's salt K[PtCl3(C2H4)].H2O, which is believed to be
the first organometallic [5], and its C-C bond length increases to 1375 picometers on bonding to
the metal [6]. This action encourages the carbon atoms to have rehybridization to sp3, which occurs by the bending back the hydrogen atoms to ethylene from the metal [7]. The mechanism of
action is quite similar to the mechanism of action of chelate agents ( figure 5).

Cl

Pt

Cl

Cl

Figure 9. Zeies’s salt.
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2.2. Experimental and characterization
2.2.1: Synthesis of DPAPlatin
A suspension of di-picolyamine (0.2 mmol) in water (5 mL) was titrated with 0.1 M
HCl with stirring until all the solid had dissolved, followed by the addition of a solution
of K2PtCl4 (0.18 mmol) in water (3 mL). The precipitate of Pt-complex is formed after
the above mixture has been refluxed at 70 ˚C for 2 h. The precipitate is collected and
washed with 0.1 M HCl, water and ethanol and then is dried at 50 ˚C under vacuum for 5
h.

K2PtCl4

N
H
N

N

H
N

H2O + HCl 70 ºC
N

Pt
Cl

73% yield

Figure 10. The mechanism of the synthesized drug “DPAPlatin”.
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2.2.2. Synthesis of PhenPlatin
1,10-phenanthrolin-5-amine (0.2 mmol) in water (5 ml) with (2 ml) of MeOH and
solution was stirred until solid was dissolved, followed by the addition of a solution of
K2PtCl4 (0.18 mmol) in water (2 ml). The precipitate of Pt-complex is formed after the
above mixture has been refluxed at 100 ˚C for 4 h. The precipitate is collected and
washed with 0.1 M HCl, water and ethanol and then is dried at 50 ˚C under rotary evaporation for 8 hours.
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Figure 11. The mechanism of the synthesized drug “PhenPlatin”.
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2.2.3 Synthesis of TriPicolyAminePlatin
125 mg of potassium tetrachloroplatinate (K2PtCl4) was added 200 µl of water via a
micro-syringe. The solution was heated with stirring in an oil bath to 70 ºC. To this a
solution of 300 mg of KI in 500 µl of warm water was added. The mixture was heated to
80 ºC with continuous stirring. As soon as the temperature reached 80 ºC, the mixture
was cooled down to room temperature. The solution was filtered using a Hirsch funnel to
remove any solid impurities. Using a syringe, 0.4 mmol of the organic compound was
added with HCl and water, after 45 min of stirring, another 0.4 mol of organic compound
is added and stirred for another 45 min. An oily complex was obtained. The beaker was
allwed to stand for an additional 20 min at room temperature [8]
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Figure 12. The mechanism of the synthesis of the synthesized drug “TriPicolyAminePlatin”.
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2.2.4. Synthesis of DiPhenPlatin
125 mg of potassium tetrachloroplatinate (K2PtCl4) was added 200 µl of water via a
micro-syringe. The solution was heated with stirring in an oil bath to 70 ºC. To this a
solution of 300 mg of KI in 500 µl of warm water was added. The mixture was heated
to 80 ºC with continuous stirring. As soon as the temperature reached 80 ºC, the mixture
was cooled down to room temperature. The solution was filtered using a Hirsch funnel
to remove any solid impurities. Using a syringe, 0.4 mmol of the organic compound was
added. As soon as the compound was added, fine red crystals of the complex precipitated. The beaker was allowed to stand for an additional 20 min at room temperature. The
product was washed with 500 µl ice-cold ethanol, followed by 1 ml ether [8].
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Figure 13. The mechanism of the synthesized drug “DiPhenPlatin”.
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2.2.5. Synthesis of DCCPlatin
The hydrate is commonly prepared from K2[PtCl4] and N,N’-dicyclohexylcarbodiimide in the
presence of a catalytic amount of SnCl2. The water of hydration can be removed in vacuo.
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Figure 14. The mechanism of the synthesized drug “DCCPlatin”.
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2.3. Results and fragmentation
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2.3.1. Characterization of DPAPlatin
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2.3.2. Characterization of PhenPlatin
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2.3.3. Characterization of TriPicolyAminePlatin
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2.3.4. Characterization of DiPhenPlatin
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2.3.5. Characterization of DCCPlatin
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For the spectra of mass spectrometry, the molecular ion and the fragmentation were calculates
as shown. And for NMR, the peaks were calculated from ChemDraw and fitted to the experimental spectra.
However, since the complexes are possible anticancer agents, they are currently being tested in
Germany by Biozentrum of Martin-Luther-Universität Halle-Wittenberg by Dr Reinhard
Paschke.
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CHAPTER 3
SUMMARY AND FUTURE WORK

3.1. Summary

The evolution of platinum-based anticancer drugs has long been concentrated on the synthesis
and assessment of complexes that can attack cancer cells without harming other normal cells.
These efforts have brought five platinum-based complexes to clinical use, which are widely employed anticancer drugs. The generality of deep-rooted and acquired resistance to platinum
treatment, however, requires the development of new complexes that operate through various
mechanisms. Despite the fact that it was initially believed to be unproductive, thousands of potential platinum-based anticancer drugs have been developed and synthesized. Additionally, different strategies were expounded and have shown promising results and can be used in the future
work and studies [1]. Regardless of the clinical success that has been realized by cisplatin, carboplatin, oxaliplatin and the other approved platinum-based drugs, the therapy with these compounds still inflicts a number of serious side-effects and disorders [2]. Among those impacts on
patient quality of life are nephrotoxicity, fatigue, emesis, alopecia, ototoxicity, peripheral neuropathy, and myelosupression [3]. In many treatment arrangements, one or more of these sideeffects will often be dose-limiting. Another major limitation of recent platinum-based drugs is
that some categories of cancer are naturally resistant to treatment and others develop resistance
with time [4]. In an attempt to avoid the mechanisms that give rise to such inherent or acquired
resistance and to decrease other side-effects, different platinum-based anticancer drugs have been
synthesized in order to form different chemical properties. The theorem is that a variation in
structure will result in an adjusted mechanism of action and, consequently, a different kind anticancer activity.
The application of any anticancer agent in the treatment of human patients is restricted by its
general level of toxicity. Various platinum-based anticancer drugs have been synthesized in the
hope of increase specificity as well as reduce side effect. This battle has introduced 5 different
platinum-based anticancer drugs, and another 10 drugs are going under clinical trial.
However, considering that the majority of these drugs function through a similar non-specific
mechanism of action, some shortcomings of cisplatin are therefore retained, albeit to a lesser extent. Thus, simple modification of the ligands seems unlikely to bring about a quality leap from
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an in discriminative drug to a ‘‘magic bullet’’. Optimally, future platinum drugs should attack
exclusively cancerous cells without affecting normal ones, and enter the former more readily
than the latter.

Five different platinum-based anticancer drugs have been synthesized in the hope of finding
drugs with higher efficacy and less or no side effect. These platinum complexes have various
leaving groups that differ from each other, such as methoxy, chloride, and water. Another option
was considered, which was having a platinum-based complex that can interact or intercalate with
target DNA without the need of leaving groups, and that was done by the synthesis of DiPhenPlaitn, as it is believed that 1,10-phenanthroline can intercalate with DNA without the necessity
of leaving groups.
Having various chemical properties in the synthesized platinum-based anticancer drugs in order to obtain a better understanding about the diversity of each drug and how it affects cancer
cells and in the hope of categorizing these drugs into aspects in order to facilitate their studies, It
was attempted to synthesize different compounds with different ligand properties, seeking to understand the differences between them all, and which one is more favorable.
I. The first category to synthesize is the chelate amine ligands; the main advantage of this form
is the cis configuration, which is the favorable form for platinum-based anticancer drugs.
Cisplatin, for example, is highly cytotoxic whereas transplatin is not cytotoxic. Two different
platinum-based complexes have been synthesized under this category, and they are Di(2-picoly)aminchloro platinum, which has one chloride as anionic ligand, and PhenPlatin, which
has four different anionic ligands, and that might enhance the opportunity to attach to the target DNA. Another unique feature that PhenPlatin can have is the ability to intercalate with
DNA without the need of having leaving group [5], and by having four additional anionic ligands, there can be a high probability of obtaining a highly reactive drug. Plus, PhenPlatin
complex has two platinum centers that can work as two different drugs when they are separated. Therefore, PhenPlatin can be a motivating drug toward cancer cells.
By having at least one leaving group in order to give the drugs the possibility to interact with
the targeted DNA it is possible to obtain a drug that can be effective toward cancer cells. The
chelate agent category has been used in the most of the approved platinum-based anticancer
drugs, which drives us to investigate more by synthesizing more platinum-based complexes under the same category.
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Di(2-picoly)aminchloro platinum

PhenPlatin

Figure 15. The synthesized platinum-based anticancer drugs under “chelate agents” category.
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Figure 16. Views of Cu(phen)2+/DNA (Copper-1,10-Phenanthroline Complexes Binding to
DNA: Structural Predictions from Molecular Simulations. J. Phys. Chem. B 2009, 113, 10881–
10890) [5].
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II. The second category of the synthesized drugs is Pt(IV)-based anticancer drugs, the octahedral
complexes that have been studied lately. Three Pt(IV) complexes are currently undergoing
clinical use, and that gives a potential hope for synthesizing more drugs that can be highly
reactive towards cancer cells. Two different platinum-based complexes have been synthesized
under the category of Pt(IV). One of these is TripicolyaminePlatin, which after the reduction
of its platinum (IV) to (II), will end up with one chloride as mono dentate anionic ligand, and
can react strongly toward target DNA and attach to the guanine in order to block the reproduction of the target DNA. The second of these platinum(IV)-based drugs is DiPhenPlatin.
This second drug has two leaving group and their loss will occur after the reduction of Pt(IV)
to Pt(II) and then the drug can intercalate with the target DNA. The reason behind the synthesis of the second drug is to obtain a drug that can be inert - “stable and not reactive” - in the
normal Pt(IV) phase, and once the drug reaches the target cell, it would lose the leaving
group to leave the drug with no anionic ligand. As mentioned above, 1,10-phenenanthroline
and its derivatives have the ability to intercalate with DNAs [5]. Thus, DiPhenPlatin can be a
promising drug that should have the ability to be stable and not reactive before reaching the
target DNA, and that means the body will not be effected by the drug before the reduction
occurs, and once the loss of the leaving group happens, and the drug will be reactive toward
the target DNA, which is proposed to be those of the cancer cells. Another special feature that
DiPhenPlatin has is the ease of losing the leaving groups which are water and methanol as
both of them work as very good leaving groups. By losing water molecule the body will not
be affected whatsoever as this amount of water is not bad to be added to the body. However,
the loss of methanol is another story, as this is toxic to the human body, which would restrict
the efficacy if it were necessary to administer it in high dosage. Nevertheless, one of the objectives is to synthesize drugs that can be administrated in low dosage; therefore the possibility to be effected by methanol that is attached to DiPhenPlatin is fairly lower than the amount
that will lead to danger to human body.
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TriPicolyAminePlatin

DiPhenPlatin

Figure 17. The synthesized platinum (IV)-based anticancer drugs.
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III. The third category is by having metal center attached to π bond of organic compounds, which
is a new field that is believed to open new options for platinum-based complexes as it provides a unique property. By rehybridizing the nitrogen and the carbon of the complex, new
properties can be provided. The first organometallic to be ever known is Zeise’s salt which
was tested for the ability to be reactive toward cancer cells. Surprisingly, Zeise’s salt showed
the capability to inhibit cyclooxygenase enzyme “COX enzyme”, and this inhibition can provide relief from the symptoms of inflammation and pain. Therefore, an important potential
for a new application of platinum-based drugs is cyclooxygenase inhibitors. COX-2 inhibitors
are pain reducers which cause less gastrointestinal side effects and bleeding than aspirin, 2(acetoxy)benzoic acid, and other NSAIDS (nonsteroidal anti-inflammatory drugs) [6]. An aspirin analog has been attached to Zeise’s salt and its derivatives in order to obtain a medical
vision whether Zeise’s salt and its derivatives can be effective or not, and it gave promising
results. It is believed that the coordination of the Zeise’s salt is the effective part of the salt
[7]. In this thesis, a platinum-based drug was synthesized that has similar coordination,
where the platinum metal center is attached to the organic compounds by the π bonds instead
of the actual atoms. By having the metal center attached to π-bond of the ethene, the C-C
bond length has increased to 1375 picometers from 1337 pm for ethylene [8]. This cooperation motivates the carbon atoms to rehybridize from sp2 to sp3, which is determined by the
bending of the hydrogen atoms on the ethylene back away from the metal [9].
The application of a cytotoxic COX inhibitor opens a new option for the therapy of tumors for
which it is known that an overexpression of COX results in pathological variations. During the
last years it was demonstrated that various mammary carcinoma show increased expression of
COX-2 and that inhibitors of this enzyme can reduce tumor growth and tumor progression. An
increased COX-2 expression in gynecologic tumors is further accompanied by a bad prognosis
for patients with mammary carcinoma as well asprostate carcinoma [10]. In order to have a further understanding, one drug has been synthesized under this category, and it is DCCPlatin. By
having the platinum attached to two π-bonds of N,N-dicyclohexylcarbodiimide, a new and
unique feature can occur, which can open a new field of new platinum-based complexes that
share similar properties. However, the new feature of DCCPlatin that no drug has, is having nitrogen that is attached to each double-bond, which can provide a special feature.
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Figure 18. Design and reactivity of potassium [2-(prop-2-enol)-2-ace- toxybenzoat]trichloroplatinate(II) (Pt-Propenol-ASS) {S. Meieranz, M. Stefanoupoulou, G. Rubner, K. Bensdorf, D.
Kubutat, W. S. Sheldrick and R. Gust. The Biological Activity of Zeise’s Salt and its Derivatives.
Angew Chem Int Ed Engl. 2015, 54(9), 2834-2837.[7]}.
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N,N- dicyclohexylcarbodiamindichloro platinum (II)

Figure 19. DCCPlatin that has the platinum attached to the π-bonds of N,N- dicyclohexylcarbodiamindichloro.
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3.2. Future work
The lack of specificity of platinum-based anticancer drugs is the main issue that needs to be
addressed in order to increase the efficacy of the drugs. Thousands of platinum complexes have
been synthesized, designed, and developed to achieve the goal where the drugs can be used with
no side effect that harms normal cells. Personally, I have synthesized eight different platinumbased anticancer drugs with different chemical properties. However, further projects can be under consideration for future studies, and they include:

3.2.1. Tethering carboxylic acid
Drug targeting and delivery represents an exceedingly active area of research for platinumbased anticancer drugs that can move directly to their biological targets [11]. Comparing with
classical chemotherapy, targeted therapy for cancers has two main benefits, which are the evasion of harming normal tissues, and control of drug resistance. In the past years, differs drug targeting and delivery paths have been promoted in a pursuit to decrease the systemic toxicity and
drug resistance of platinum-based anticancer drugs [12]. The eventual objective of these attempts
is to gain platinum drugs that are supremely selective for tumor tissues and can be distributed at
lower doses with less side effects and an enhanced therapeutic index [13]. Carriers such as estrogens, carbohydrates, carbon nanotubes, and nanoparticles would be possible candidates. As
indicated in other literature (Xiaoyong Wang and Zijian Guo. 2013) these carriers have shown
very promising results.

3.2.2. More of platinum-based (IV) anticancer drugs
Amid the figure of the prepared and biomedically screened platinum complexes, octahedral
complexes with platinum(IV) center, including satraplatin, tetraplatin, iproplatin, and ormaplatin,
have been tested as potential anticancer agents particularly against cisplatin resistant tumor cell
lines [14]. Pt(IV) complexes with octahedral structure have advantages over the Pt(II) complexes
because of their kinetic inertness. This controls release of Pt(II) and and thus toxicity is less
compared to Pt(II) analogs [15]. Pt(IV) drugs are considered prodrugs because they need to be
reduced intra- or extra-cellularly by biological reductants such as glutathione, ascorbic acid, and
cystein to Pt(II) complexes in order to become reactive. Based on a literature work (Hien T. T.
Duong, Vien T. Huynh, Paul de Souza, and Martina H. Stenzel. 2010) platinum-based (IV) anticancer drugs can give a very hopeful result [16].
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3.2.3. Tethering carboxylic acid
The transformation of neutral platinum(II) drugs is necessary in order to get a reactive bifunctional electrophile outcomes in the coordinate binding of the nucleophilic bases in the DNA.
However, the existence of the very slow-leaving oxalic acid group in some platinum complexes
has led to a realization that other mechanisms might also exist for the prodrug activation. Additionally, the presence of the carboxylic acids can greatly enhance the reactive oxygen species,
ROS, that is produced by platinum-based drug complexes. The enhanced ROS could eventually
moderate the cellular damage, leading to the developed cytotoxicity via the apoptosis pathway.
Accordingly, it is noticed that the carborane–carboxylic acid derivatives either monodentate carboxylic acid, or bidentate carboxylic acid show an obvious effect on the biological toxicities of
platinum-based drug complexes toward cancer cells, even stronger than the carboranes, which
have no enhanced effect on the cytotoxicity. It is suggest that the negatively charged carboxylic
groups in carborane–carboxylic acids can readily lead to self-assembled composites of the carborane–carboxylic acid derivatives on the positively charged surface of Platinum-based drug complexes through electrostatic interactions [17].
An example to take, carboplatin, which was introduced as a second generation anticancer drug
during the mid-1980s [18] in response to the severe side effects exhibited by its predecessor, cisplatin. Since then, this drug has gained wide acceptance in the clinical treatment of different cancers [19], the dose- limiting factor being myelosuppression. Carboplatin possesses a slowly
aquating, ringlike, bulky side group, i.e. the 1,1-cyclobutanedicarboxylato group, instead of the
readily leaving chloro groups in cisplatin. Therefore, attaching carboxylic acid to the synthesized
platinum-based anticancer drugs is worth trying.
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